LEIOMYOSARCOMA

This study tests a daily pill called AL3818 (anlotinib) for people with a rare cancer called alveolar soft part sarcoma (ASPS) that has spread. The goal is to see if the drug can shrink tumors or slow the cancer. About 325 adults with ASPS are being enrolled. Participants take th…

This early-phase trial tests a combination of two drugs, gemcitabine and nab-sirolimus, in people with advanced leiomyosarcoma or other soft-tissue sarcomas that have lost function in the TSC1 or TSC2 genes. The main goal is to find a safe dose and watch for side effects. Up to 1…

This study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…

This study is for people with bone sarcomas who have finished their first round of treatment. It tests whether taking the drug regorafenib for up to 12 months can help keep the cancer from returning, compared to just being watched. About 168 participants will be randomly assigned…

This study tests whether giving a shorter course of radiation (3 weeks instead of longer) before surgery for soft tissue sarcoma can reduce long-term side effects. Each patient's treatment is personalized by choosing between proton or standard X-ray radiation. The study will enro…

This study tests whether Ivonescimab can safely shrink or control advanced leiomyosarcoma, a rare soft-tissue cancer. About 20 adults who have already tried 1-3 other treatments will receive the drug. The goal is to see if the tumor stops growing or shrinks, while keeping side ef…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or slow advanced leiomyosarcoma, a rare soft-tissue cancer. About 16 adults whose cancer worsened after standard chemotherapy will receive ATRA pills for 3 days before each cemiplimab infusion, then cemip…

This study tests whether giving chemotherapy before surgery helps people with high-risk retroperitoneal sarcoma (a rare cancer in the abdomen) live longer without the cancer coming back. About 250 adults with specific sarcoma types will be randomly assigned to receive chemo then …

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy can help shrink or control advanced soft tissue sarcomas that cannot be removed by surgery. About 45 adults aged 18-75 with certain sarcoma types will receive the combination as their fir…

This study looks at whether a blood test for tumor DNA can help doctors know early if chemotherapy is working for people with advanced leiomyosarcoma, a rare soft tissue cancer. Researchers will collect blood samples before and during treatment, along with tumor tissue and scans,…

This study looks at whether a blood test for tumor DNA (ctDNA) and detailed scans can help predict how well chemotherapy works in people with a rare soft tissue cancer called leiomyosarcoma. About 40 participants will give blood samples and have scans before, during, and after tr…